Milestone Pharmaceuticals Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
On June 18, 2026, Joseph Oliveto, our President and Chief Executive Officer, terminated a Rule 10b5-1 trading plan effective June 18, 2026. As of the termination of the Rule 10b5-1 trading plan, 80,000 shares of our common shares were sold under the plan. Prior to its termination, the plan had provided for the potential sale of up to 2,128,588 common shares. Transactions under Mr. Oliveto’s plan were based upon pre-established dates and stock price thresholds and only occurred upon the expiration of the applicable mandatory cooling-off period. Mr. Oliveto’s plan had a termination date of January 2, 2027, or the date all shares subject to the plan had been sold.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.